neodymium

(redirected from Neodyne)
Also found in: Dictionary, Thesaurus, Encyclopedia.

neodymium

 (Nd) [ne″o-dim´e-um]
a chemical element, atomic number 60, atomic weight 144.24. (See Appendix 6.)

ne·o·dym·i·um (Nd),

(nē'ō-dim'ē-ŭm),
One of the rare earth elements; atomic no. 60, atomic wt. 144.24.
[neo-, new, + G. didymos, twin (of lanthanum)]

neodymium

/neo·dym·i·um/ (Nd) (-dim´e-um) a chemical element, at. no. 60.

neodymium (Nd)

an element with the atomic number of 60. A rare earth metal, neodymium has many industrial uses. Neodymium dust is highly irritating to eyes and mucous membranes.

ne·o·dym·i·um

(nē'ō-dim'ē-ŭm)
One of the rare earth elements; atomic no. 60, atomic wt. 144.24.
[neo-, new, + G. didymos, twin (of lanthanum)]

neodymium (Nd) (nē´ōdim´ēəm),

n a rare earth element with an atomic number of 60 and an atomic weight of 144.24.

neodymium

a chemical element, atomic number 60, atomic weight 144.24, symbol Nd. See Table 6.

neodymium:yttrium-aluminum-garnet (Nd:YAG) laser
a type of continuous wave laser used for hemostasis, coagulation and in ophthalmic surgery for ablation of specific structures.
References in periodicals archive ?
About Neodyne Industries Neodyne Industries is a leading global provider of highly engineered industrial solutions and aftermarket parts and services serving a broad array of end-markets.
The acquisition of Neodyne Industries is the fourth investment from BC Partners' ninth fund which held its final closing on $8.
Neodyne is committed to providing clinically proven technologies to both surgeons and patients looking to minimize scarring," said Bill Beasley, President of Neodyne Biosciences, "embrace is the first scar management product of its kind, and to our knowledge, no other scar treatment is backed by the same wealth of clinical data.
The newly issued patent is owned by Neodyne Biosciences and is accessible on the USPTO's website at www.
We're excited to share the results of this study, which further demonstrates our commitment to providing clinically proven technologies to both surgeons and patients looking to mitigate scarring," said Bill Beasley, President of Neodyne Biosciences.
This marks the 7th issued patent in the Neodyne Biosciences portfolio and further supports the company's first product, embrace Advanced Scar Therapy, which received 510(k) clearance from the US Food and Drug Administration (FDA) in September, 2011.
Adding another patent to our intellectual property portfolio strengthens our position in the marketplace as we continue to address physician and patient demand for an effective treatment of post-surgical scarring," said Bill Beasley, President of Neodyne Biosciences.
Michael Longaker, a founder and Chair of the Board of Directors of Neodyne Biosciences, commended Dr.
Neodyne Biosciences announced its first commercial sale of its product in February of this year.
We are excited to commercially launch embrace (TM) scar therapy in the United States and believe that our patented scar therapy can become the treatment-of-choice for those patients concerned with the risk of post-surgical scarring," said Bill Beasley, President and COO of Neodyne.